KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Invested Capital (2016 - 2025)

Historic Invested Capital for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $838.3 million.

  • Neogenomics' Invested Capital fell 769.87% to $838.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $838.3 million, marking a year-over-year decrease of 769.87%. This contributed to the annual value of $902.3 million for FY2024, which is 416.32% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Invested Capital is $838.3 million, which was down 769.87% from $854.0 million recorded in Q2 2025.
  • Neogenomics' 5-year Invested Capital high stood at $1.1 billion for Q2 2021, and its period low was $838.3 million during Q3 2025.
  • Moreover, its 5-year median value for Invested Capital was $947.4 million (2023), whereas its average is $969.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 4031.66% in 2021, then plummeted by 1092.61% in 2022.
  • Neogenomics' Invested Capital (Quarter) stood at $1.1 billion in 2021, then fell by 9.95% to $998.0 million in 2022, then fell by 5.66% to $941.5 million in 2023, then decreased by 4.16% to $902.3 million in 2024, then dropped by 7.1% to $838.3 million in 2025.
  • Its Invested Capital was $838.3 million in Q3 2025, compared to $854.0 million in Q2 2025 and $888.3 million in Q1 2025.